How good is the evidence base for test selection in clinical guidelines?

Clinica Chimica Acta

Volumn 432, Issue , 2014, Pages 27-32

  Misra, Shivani ^a   Barth, Julian H ^b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Audit; Evidence based; Guidelines; Quality; Test selection

Indexed keywords

ARTICLE; CLINICAL PATHWAY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; EVIDENCE BASED PRACTICE; LABORATORY TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; QUALITY CONTROL; STANDARDIZATION; DIAGNOSTIC PROCEDURE; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL ERROR; PROCEDURES;

CLINICAL LABORATORY TECHNIQUES; EVIDENCE-BASED MEDICINE; HUMANS; MEDICAL ERRORS; PRACTICE GUIDELINES AS TOPIC;

EID: 84901609615     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.01.040     Document Type: Article

References (49)

1. Sackett D.L., Rosenberg W.M.C., Gray J.A.M., Haynes R.B., Richardson W.S. Evidence based medicine: what it is and what it isn't. Br Med J 1996, 213:71-72.
2. Bossuyt P.M.M., Reitsma J.B., Linnet K., Moons K.G.M. Beyond diagnostic accuracy: the clinical utility of diagnostic tests. Clin Chem 2012, 58:1636-1643.
3. Price C.P. Evidence-based laboratory medicine: supporting decision-making. Clin Chem 2000, 46:1041-1050.
4. Bossuyt P.M., Irwig L., Craig J., Glasziou P. Comparative accuracy: assessing new tests against existing diagnostic pathways. Br Med J 2006, 332:1089-1092.
5. Bossuyt P.M.M., McCaffery K. Additional patient outcomes and pathways in evaluations of testing. Med Decis Making 2009, 29:E30-E38.
6. Verrilli D., Welch H. The impact of diagnostic testing on therapeutic interventions. J Am Med Assoc 1996, 275:1197-1198.
7. Barth J.H., Jones R.G. Indiscriminate investigations have adverse effects. Br Med J 2003, 326:393.
8. Van Walraven C., Naylor C.D. Do we know what inappropriate laboratory utilization is? A systematic review of laboratory clinical audits. JAMA 1998, 280:550-558.
9. Bindels R., Winkens R.A., van Wersch J.W., Pop P., Hasman A. Reliability of the assessment of appropriateness of diagnostic test request behavior. Stud Health Technol Inform 2001, 84:1112-1115.
10. Lijmer J.G., Leeflang M., Bossuyt P.M.M. Proposals for a phased evaluation of medical tests. Med Decis Making 2009, 29:E13-E21.
11. Teutsch S.M., Bradley L.A., Palomaki G.E., et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP working group. Genet Med 2009, 11:3-14.
12. Asanuma K. Clinical evidence for IVD medical devices - scientific validity determination and performance evaluation http://www.imdrf.org/docs/ghtf/final/sg5/technical-docs/ghtf-sg5-n8-2012-clinical-performance-studies-ivd-medical-devices-121102.pdf.
13. Ferrante di Ruffano L., Hyde C.J., McCaffery K.J., Bossuyt P.M.M., Deeks J.J. Assessing the value of diagnostic tests: a framework for designing and evaluating trials. Br Med J 2012, 344:e686.
14. Lord S.J., Irwig L., Bossuyt P.M.M. Using the principles of randomized controlled trial design to guide test evaluation. Med Decis Making 2009, 29:E1-E12.
15. Bossuyt P.M., Lijmer J.G., Mol B.W. Randomised comparisons of medical tests: sometimes invalid, not always efficient. Lancet 2000, 356:1844-1847.
16. Lijmer J.G., Mol B.W., Heisterkamp S., et al. Empirical evidence of design-related bias in studies of diagnostic tests. J Am Med Assoc 1999, 282:1061-1066.
17. Talwar S., Siebenhofer A., Williams B., Ng L. Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP. Heart 2000, 83:278-282.
18. Burri E., Hochholzer K., Arenja N., et al. B-type natriuretic peptide in the evaluation and management of dyspnoea in primary care. J Intern Med 2012, 272:504-513.
19. Van Rheenen P.F., Van de Vijver E., Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. Br Med J 2010, 341. [c3369-c3369].
20. National Institute of Clinical Excellence Chest pain of recent onset, NICE clinical guideline 95 2010.
21. National Institute of Clinical Excellence Ovarian cancer; the recognition and initial management of ovarian cancer, NICE clinical guideline 122 2011.
22. Van Deventer H.E., Miller W.G., Myers G.L., et al. Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population. Clin Chem 2011, 57:490-501.
23. Maskell N.A., Butland R.J. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax 2003, 58(Suppl. 2):ii8-ii17.
24. Lapworth R., Tarn A.C. Commentary on the British Thoracic Society guidelines for the investigation of unilateral pleural effusion in adults. Ann Clin Biochem 2006, 43:17-22.
25. Aakre K.M., Langlois M.R., Watine J., et al. Critical review of laboratory investigations in clinical practice guidelines: proposals for the description of investigation. Clin Chem Lab Med 2012, 51:1217-1226.
26. Whiting P., Rutjes A.W., Reitsma J.B., Bossuyt P.M., Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003, 3:25.
27. Whiting P.F., Weswood M.E., Rutjes A.W., Reitsma J.B., Bossuyt P.N., Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006, 6:9.
28. Bossuyt P.M., Reitsma J.B., Bruns D.E., et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for reporting of diagnostic accuracy. Clin Chem 2003, 49:1-6.
29. Krzych L.J., Liszka L. No improvement in studies reporting the diagnostic accuracy of B-type natriuretic peptide. Med Sci Monit 2009, 15:SR5-14.
30. Coppus S.F.P.J., Van Der Veen F., Bossuyt P.M.M., Mol B.W.J. Quality of reporting of test accuracy studies in reproductive medicine: impact of the standards for reporting of diagnostic accuracy (STARD) initiative. Fertil Steril 2006, 86:1321-1329.
31. Smidt N., Rutjes A.W.S., Van Der Windt D.A.W.M., et al. The quality of diagnostic accuracy studies since the STARD statement: has it improved?. Neurology 2006, 67:792-797.
32. Wilczynski N.L. Quality of reporting of diagnostic accuracy studies: no change since STARD statement publication-before-and-after study. Radiology 2008, 248:817-823.
33. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005, 93:387-391.
34. Brouwers M.C., Kho M.E., Browman G.P., et al. The Global Rating Scale complements the AGREE II in advancing the quality of practice guidelines. J Clin Epidemiol 2012, 65:526-534.
35. Bossuyt P.M.M. Room for improvement in national academy of clinical biochemistry laboratory medicine practice guidelines. Clin Chem 2012, 58:1392-1394.
36. Watine J., Friedberg B., Nagy E., et al. Conflict between guideline methodologic quality and recommendation validity: a potential problem for practitioners. Clin Chem 2006, 52:65-72.
37. Don-Wauchope A.C., Sievenpiper J.L., Hill S.a, Iorio A. Applicability of the AGREE II instrument in evaluating the development process and quality of current National Academy of Clinical Biochemistry guidelines. Clin Chem 2012, 58:1426-1437.
38. Sacks D.B., Arnold M., Bakris G.L., et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011, 34:e61-e99.
39. Guyatt G.H., Oxman A.D., Vist G.E., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J 2008, 336:924-926.
40. Schünemann H.J., Oxman A.D., Brozek J., et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. Br Med J 2008, 336:1106-1110.
41. Tricoci P., Allen J.M., Kramer J.M., Califf R.M., Smith S.C. Scientific evidence underlying the ACC/AHA clinical practice guidelines. J Am Med Assoc 2009, 301:831-841.
42. Lee D.H., Vielemeyer O. Analysis of overall level of evidence behind Infectious Diseases Society of America practice guidelines. Arch Intern Med 2011, 171:18-22.
43. Roos M., Brodbeck J., Sarkozy A., Chierchia G.B., De Asmundis C., Brugada P. A critical analysis of the scientific evidence behind international guidelines related to cardiac arrhythmias. Circ Arrhythm Electrophysiol 2011, 4:202-210.
44. Hazlehurst J.M., Armstrong M.J., Sherlock M., et al. Methodological assessment in endocrinology. A comparative quality assessment of evidence-based clinical guidelines in endocrinology. Clin Endocrinol (Oxf) 2013, 44:183-190.
45. Wartofsky L., Dickey R.A. The evidence for a narrower thyrotropin reference range is compelling. J Clin Endocrinol Metab 2005, 90:5483-5488.
46. Surks M.I., Goswami G., Daniels G.H. The thyrotropin reference range should remain unchanged. J Clin Endocrinol Metab 2005, 90:5489-5496.
47. Sturgeon C.M., Hoffman B.R., Chan D.W., et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem 2008, 54:e1-e10.
48. Parliamentary discussion on Haute Autorite Sante recommendations [Internet]. [cited 2013 Apr 11]. Available from. http://www.assemblee-nationale.fr/14/cri/2012-2013/20130187.asp#P2575_6668.
49. Barth J.H. Clinical quality indicators in laboratory medicine: a survey of current practice in the UK. Ann Clin Biochem 2011, 48:238-240.